Do Predictors Exist for a Successful Withdrawal of Preoperative Prostaglandin E1 from Neonates with d-Transposition of the Great Arteries and Intact Ventricular Septum?
- 1 October 2010
- journal article
- research article
- Published by Springer Nature in Pediatric Cardiology
- Vol. 31 (8) , 1198-1202
Abstract
Prostaglandin E1 (PGE1) is given to neonates with d-transposition of the great arteries (d-TGA) to reduce cyanosis by reopening and maintaining the patency of the ductus arteriosus. To avoid side effects, this medication can be stopped for hemodynamically stable patients after balloon atrial septostomy (BAS). A consecutive series of neonates with d-TGA and an intact ventricular septum (IVS) presenting from 2000 through 2005 was analyzed retrospectively to search for side effects of PGE1 and to identify predictors for a safe preoperative withdrawal. The medication was stopped for hemodynamically stable patients with transcutaneous oxygen saturations higher than 80% after BAS and reinitiated for patients with an oxygen saturation lower than 65%. Patients successfully weaned were compared with those who had failed weaning in terms of atrial septal defect (ASD) size, ductus arteriosus size, and the transcutaneous oxygen saturation. Prostaglandin E1 was initiated for all 43 neonates with d-TGA. The median maintenance dose of PGE1 was 0.00625 μg/kg/min (range, 0.00313–0.050 μg/kg/min) for a median duration of 6 days (range, 1–12 days). For 16 patients, PGE1 was preoperatively withdrawn but then had to be reinitiated for 7 of the 16 patients. No predictors for a successful weaning of PGE1 were found based on ASD size, ductus arteriosus size, or oxygen saturation. The adverse effects of PGE1 were apnea in 10 patients and fever in 19 patients. Neither seizures nor necrotizing enterocolitis was documented. Prostaglandin E1 was successfully withdrawn for a minority of hemodynamically stable patients with d-TGA. No predictors for a successful weaning could be identified. Because apnea and fever are common side effects, withdrawal of PGE1 after BAS may improve patient safety and comfort. In this patient group, if PGE1 withdrawal was not well tolerated, it could be safely reinitiated. There were no serious side effects of PGE1.Keywords
This publication has 12 references indexed in Scilit:
- Early discontinuation of intravenous prostaglandin E1 after balloon atrial septostomy is associated with an increased risk of rebound hypoxemiaJournal of Perinatology, 2008
- [Complications of prostaglandin E1 treatment of congenital heart disease in paediatric medical intensive care].2005
- Interventional Cardiology--StentsEuropean Heart Journal, 1994
- Role of balloon atrial septostomy before early arterial switch repair of transposition of the great arteriesJACC, 1992
- Histopathology of the arterial duct (ductus arteriosus) with and without treatment with prostaglandin E1International Journal of Cardiology, 1988
- Prostaglandin E2 administration in infants with ductus-dependent cyanotic congenital heart diseaseEuropean Journal of Pediatrics, 1987
- Effects of prostaglandin E1 infusion in the pre-operative management of critical congenital heart disease.The Tohoku Journal of Experimental Medicine, 1985
- Evaluation of Alprostadil (Prostaglandin E1) in the Management of Congenital Heart Disease in InfancyPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 1982
- Side effects of therapy with prostaglandin E1 in infants with critical congenital heart disease.Circulation, 1981
- Prostaglandins, ductus arteriosus, pulmonary circulation: Current concepts and clinical potentialEuropean Journal of Clinical Pharmacology, 1980